Performance of UF-5000 parameters, dysmorphic RBC (%), and urinary protein concentration for GH in the derivation and validation cohorts
AUC (95% CI) | Ideal cut-off | Derivation cohort | Validation cohort |
||||
---|---|---|---|---|---|---|---|
Sensitivity% (95% CI) | Specificity% (95% CI) | Sensitivity% (95% CI) | Specificity% (95% CI) | ||||
URD (%) | 0.814 (0.744–0.872) | <0.001 | >20.1 | 99.0 (94.6–100) | 50.9 (37.1–64.6) | 89.4 (76.9–96.5) | 63.3 (49.9–75.4) |
Small RBC (%) | 0.814 (0.744–0.872) | <0.001 | >30.1 | 93.1 (86.2–97.2) | 60.0 (45.9–73.0) | 83.0 (69.2–92.4) | 68.3 (55.0–79.7) |
Lysed RBC (%) | 0.704 (0.626–0.774) | <0.001 | >1.7 | 71.3 (61.4–79.9) | 61.8 (47.7–74.6) | 53.2 (38.1–67.9) | 65.0 (51.6–76.9) |
RBC-P70FSC (ch) | 0.815 (0.745–0.873) | <0.001 | ≤138 | 96.0 (90.2–98.9) | 56.4 (42.3–69.7) | 83.0 (69.2–92.4) | 65.0 (51.6–76.9) |
RBC-SF-FSC-W (ch) | 0.627 (0.546–0.703) | 0.017 | >30 | 93.1 (88.2–97.2) | 43.6 (30.3–57.7) | 87.2 (74.3–95.2) | 53.3 (40.0–66.3) |
Mean FSC |
0.798 (0.725–0.859) | <0.001 | ≤113 | 96.9 (91.1–99.4) | 52.73 (38.8–66.3) | - | - |
Dysmorphic RBC (%) |
0.683 (0.583–0.772) | <0.001 | >0 | 61.5 (49.8–72.3) | 73.9 (51.6–89.8) | 57.7 (36.9–76.7) | 37.5 (15.2–64.6) |
Urinary protein concentration (mg/L) |
6.78 (5.83–7.63) | 0.021 | >190 | 800 (705–875) | 667 (410–867) | 702 (551–827) | 483 (295–675) |
*Sensitivity and specificity in the validation cohort were calculated by applying the cut-off obtained from the derivation cohort; †Mean FSC and SSC values were not obtained in validation cohort; ‡101 and 42 of samples had accompanying dysmorphic RBC(%) results in the derivation and validation cohorts, respectively; §113 and 76 of samples had accompanying urinary protein concentration results in the derivation and validation cohorts, respectively.
Abbreviations: GH, glomerular hematuria; AUC, area under the curve; CI, confidence interval; URD, urinary RBC distribution; RBC, red blood cell; SF, surface channel; FSC, forward-scattered light; ch, channel; W, width.
© Ann Lab Med